Please ensure Javascript is enabled for purposes of website accessibility

Reckitt Benckiser Pharmaceuticals spinoff expected by end of the year

Reckitt Benckiser Pharmaceuticals spinoff expected by end of the year

Listen to this article

Richmond-based Reckitt Benckiser Pharmaceuticals Inc. (RBP) should be spun-off from its parent company by the end of the year, the company said Tuesday.

The pharmaceutical company should be separated from United Kingdom-based Reckitt Benckiser Group plc (RB) by Dec. 31.  RB, a consumer goods company, announced the spinoff plans in July.

RBP offers medicine to treat opioid dependence, including Suboxone Sublingual Film, a dissolvable film which is placed under the tongue to help reduce opioid withdrawals and cravings. It also recently partnered with AntiOp Inc. to develop a nasal spray to help treat opioid overdoses.

RBP will operate independently under Indivior PLC, which will be listed on the London Stock Exchange.

-
YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.